A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver CancerPLCor Biliary Tract Carcinoma (BTC)
Latest Information Update: 10 Feb 2023
At a glance
- Drugs Camrelizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Rivoceranib
 - Indications Biliary cancer; Gallbladder cancer; Liver cancer
 - Focus Adverse reactions
 - Sponsors Jiangsu Hengrui Medicine Co.
 
Most Recent Events
- 26 Apr 2022 Planned End Date changed from 1 Mar 2019 to 1 Apr 2022.
 - 26 Apr 2022 Planned primary completion date changed from 1 Nov 2018 to 1 Apr 2022.
 - 11 Nov 2021 Status changed from recruiting to completed according to results published in the International Journal of Cancer.